Previous 10 | Next 10 |
2023-08-03 09:05:43 ET Aravive ( ARAV ) -58% announces top-line results from phase 3 AXLerate-OC study of batiraxcept in patinum-resistant ovarian cancer. Vicarious Surgical ( RBOT ) -41% on pricing $45M offering . DXC Technology Company ( DXC ) -24% ...
2023-08-03 08:13:29 ET Lantheus Holdings ( NASDAQ: LNTH ) announced a divestiture of the sales-based royalty rights of its opioid antagonist RELISTOR. The company said the sale of this non-core asset allows it to focus on the core radiopharmaceutical business. HealthCare R...
2023-08-03 07:16:38 ET Lantheus press release ( NASDAQ: LNTH ): Q2 Non-GAAP EPS of $1.54 beats by $0.23 . Revenue of $321.7M (+43.8% Y/Y) beats by $15.04M . For further details see: Lantheus Non-GAAP EPS of $1.54 beats by $0.23, revenue of $321.7M beats b...
BEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians...
Worldwide revenue of $321.7 million for the second quarter 2023, representing an increase of 43.8% from the prior year period GAAP net income of $94.1 million for the second quarter 2023, compared to GAAP net income of $43.1 million in the prior year period GAAP fully diluted net ...
2023-08-02 16:12:02 ET Lantheus ( NASDAQ: LNTH ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is $1.31 (+47.2% Y/Y) and the consensus Revenue Estimate is $306.66M (+37.1% Y/Y). Over the last 2 year...
2023-08-01 00:23:22 ET Summary POINT Biopharma has two therapies in Phase 3 development with fast track designation, which creates the potential for positive catalysts as early as this year. Positive results from the Phase 2 study of PNT2002 provide optimism for successful results...
BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023, to discuss its financial and operating results for the second qua...
2023-06-18 03:54:38 ET Summary Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The attractive low valuation and strong growth makes it likely that Lantheus' stock outperforms ove...
BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, ann...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acqu...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...